These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23847696)

  • 1. The Integrated Web Portal for Escalation with Overdose Control (EWOC).
    Wang H; Tighiouart M; Huang SC; Berel D; Cook-Wiens G; Bresee C; Li Q; Rogatko A
    Open Med Inform J; 2013; 7():18-23. PubMed ID: 23847696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial.
    Micallef S; Sostelly A; Zhu J; Baverel PG; Mercier F
    Contemp Clin Trials Commun; 2022 Apr; 26():100901. PubMed ID: 35198796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of EWOC principle in BLRM design for phase 1 oncology trials.
    Guo X; Kent S; Maity A; Zhong W
    J Biopharm Stat; 2024 Apr; ():1-17. PubMed ID: 38562014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
    Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
    BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-finding approach for dose escalation with overdose control considering incomplete observations.
    Mauguen A; Le Deley MC; Zohar S
    Stat Med; 2011 Jun; 30(13):1584-94. PubMed ID: 21351289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding.
    Rogatko A; Cook-Wiens G; Tighiouart M; Piantadosi S
    Entropy (Basel); 2015 Aug; 17(8):5288-5303. PubMed ID: 27156869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incoherent dose-escalation in phase I trials using the escalation with overdose control approach.
    Wheeler GM
    Stat Pap (Berl); 2018 Jun; 59(2):801-811. PubMed ID: 29875549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
    Tighiouart M; Liu Y; Rogatko A
    PLoS One; 2014; 9(3):e93070. PubMed ID: 24663812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A web tool for designing and conducting phase I trials using the continual reassessment method.
    Wages NA; Petroni GR
    BMC Cancer; 2018 Feb; 18(1):133. PubMed ID: 29402249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
    Chen Z; Li Z; Zhuang R; Yuan Y; Kutner M; Owonikoko T; Curran WJ; Kowalski J
    PLoS One; 2017; 12(1):e0170187. PubMed ID: 28125617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.
    Diniz MA; Kim S; Tighiouart M
    J Probab Stat; 2018; 2018():. PubMed ID: 30906326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
    Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
    Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.
    Diniz MA; Kim S; Tighiouart M
    Stats (Basel); 2020 Sep; 3(3):221-238. PubMed ID: 33073179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
    Tighiouart M; Rogatko A; Babb JS
    Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
    Zhou H; Yuan Y; Nie L
    Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
    Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
    Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.
    Cheng JD; Babb JS; Langer C; Aamdal S; Robert F; Engelhardt LR; Fernberg O; Schiller J; Forsberg G; Alpaugh RK; Weiner LM; Rogatko A
    J Clin Oncol; 2004 Feb; 22(4):602-9. PubMed ID: 14966084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.